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Long-term survival of a patient suffering from glioblastoma 
multiforme of the brain as well as kidney cancer diagnosed and treated 
simultaneously
Zdzisława Rugała 
Primary tumors of the brain account for up to 2% of all malignant neoplasms. The average life expectancy for pa-
tients with malignant gliomas of the brain is 12. 6 months. Glioblastoma multiforme is the most common one. Most 
patients diagnosed with it die within the first two years after the date of diagnosis. Only 2% of all cases survive for 
more than 36 months. 
Renal cell carcinoma (RCC) accounts for 2–3% of all malignant neoplasms in adults. The incidence of RCC, at all levels 
of advancement, has increased in recent years, resulting in increased mortality. Average survival with this diagnosis 
is about 50% and depends on the severity of the disease. 
We present the case of a 62-year-old patient, who has survived for many years after radical treatment of glioblastoma 
multiforme of the brain. The patient was simultaneously diagnosed with kidney cancer. Before the final diagnosis was 
given, a detailed diagnostic process had been carried out at several medical institutions. The diagnostics were initiated 
as a result of an epileptic seizure that had occurred for the first time in the patient’s life. Radiological examination led 
to the suspicion of metastases to the brain as well as a tumor of the right kidney. The treatment started with surgery 
of the brain tumor. Afterward, radical removal of the right kidney was performed. 
After obtaining the final histopathological results from the brain tumor histopathological preparations were consulted 
in another city and medical center. Next, the patient received complementary radiotherapy to the site of tumor remo-
val, combined with temozolomide and continuation of chemotherapy after irradiation was finished. The treatment 
of the kidney cancer was finalized with a surgery. To date, the patient has survived for more than six years without 
relapse or neoplastic dissemination, in very good general and neurological condition. 
The case analysis allows for identifying, in the patient, several prognostic factors of long-term survival, such as: the 
relatively young age of the patient when the disease was diagnosed, good general and neurological condition before 
treatment, small size of the tumor, radical surgical treatment, location of the tumor outside of the lateral ventricles, no 
contact of the tumor with the subventricular zone of the brain (SVZ), as well as the low HDL (high-density lipoprotein) 
and LDL (low-density lipoprotein) levels in biochemical blood tests before surgery of the brain tumor.
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Introduction
Primary tumors of the brain account for up to 2% of all 
malignant neoplasms. The incidence of primary malignant 
neoplasms of the brain and other neoplasms of the central 
nervous system in Poland is approx. 3000 cases per year [1]. 
The probability of developing this neoplasm increases with 
age and amounts to 60% among brain tumors, and even 
80% if the person is 60 years of age or older. The average 
life expectancy for patients with malignant gliomas of the 
brain is 12. 6 months [2]. Most patients diagnosed with it 
die within the first two years after the date of diagnosis [3]. 
Only 2% of all cases survive for more than 36 months [4]. 
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Primary renal neoplasms constitute approximately 3% 
of all malignant neoplasms in adults [5]. The most common 
histological type is the renal cell carcinoma, which accounts 
for about 85–90%. It is the most common type of kidney 
cancer and one with a poor prognosis. Average survival with 
this diagnosis is about 50% and depends on the severity of 
the disease [5]. 
The article presents the case of a patient who has sur-
vived for many years in good general condition, without 
any neurological deficits, after simultaneous treatment for 
a primary brain tumor in the most malignant form — glio-
blastoma multiforme — and an advanced malignant kidney 
neoplasm detected locally at the same time. 
Case description
The patient, age 56, was admitted to the neurological 
department as a matter of urgency in February 2012 due 
to a sudden loss of consciousness, a convulsive seizure with 
disorders of consciousness, and consequent left-side pare-
sis. These symptoms had occurred for the first time in the 
patient’s life. CT (computed tomography) of the head was 
performed which showed, in the right temporal lobe, a hy-
podense area not amplified after administering contrast, 
with an edema and mass effect, leading to the suspicion 
of a metastatic lesion. The neurological department ap-
plied antiedematous treatment, which resulted in a rapid 
improvement in the patient’s general and neurological con-
dition. The diagnostics were expanded by an MRI (magnetic 
resonance images) examination of the head. Lumbar punc-
ture was also performed, which ruled out a neuroinfection. 
The MRI examination showed, peripherally in the 
right temporal lobe, a structure of high signal intensity in 
T2-weighted images, low signal intensity in T1 SE images, 
amplified heterogeneously and mostly marginally after con-
trast administration, with a diameter of approx. 13 mm, 
most probably a metastasis of a neoplastic disease. Around 
it, there was an extensive edematous area with a width of 
about 3.5 cm. The ventricular system on the right side was 
pressured at the level of the anterior horns. Lateral ventricles 
displaced to the left, by 3–4 mm. Figures 1–3 show images 
with this study MRI. 
During the stay at the ward, an ultrasound examination 
was also performed of the abdominal organs, and then a CT 
of the abdominal cavity. These showed, in the upper-exter-
nal part of the right kidney, a heterogeneous hypodense 
area strongly amplified by the contrast medium, with the 
dimensions of 61 × 43 × 81 mm. In addition, a complete 
blood count and biochemical blood tests were performed 
for, among others, the level of total cholesterol, as well as 
its HDL and LDL fractions. A dissemination to the lungs 
was ruled out in the CT of the chest. Then, the patient was 
transferred to the Department of Neurosurgery where, in 
March 2012, a right-side temporal craniotomy was per-
formed. After the surgery, no neurological deficits occurred 
in the patient. During the patient’s stay at the neurosurgical 
department, an urological consultation took place, after 
which he was qualified for surgical treatment of the right 
kidney tumor. In April 2012, right-side nephrectomy was 
performed without complications. The diagnosis obtained in 
the histopathological results of the radically removed kidney 
was carcinoma clarocellulare which superficially infiltrated 
the fibrous capsule of the organ. The level of advancement 
was determined at pT2N0M1 (metastasis to the brain). How-
ever, the histopathological results from the operated brain 
Figure 1 . MRI before surgery. Axial T1-weighted image: tumor in the 
right temporal lobe mostly marginally after administering contrast
Figure 2 . MRI before surgery. Axial T2-weighted FLAIR image show an 
extensive edematous area around the tumor in right temporal lobe
Figure 3 . MRI before surgery. Sagital T1-weighted image. Tumor with 
an extensive edematous area around it in the right temporal lobe
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tissue demonstrated a neoplasm of glial origin IHC: CK1(–), 
GFAP(+). Therefore, the preparations were sent for consulta-
tion to another oncology center. The consultation confirmed 
the second independent neoplastic process: glioblastoma 
multiforme G IV. A follow-up MRI of the brain, performed in 
May 2012, showed the condition after surgery of the right 
temporal lobe’s tumor. Peripherally, in the right temporal 
lobe, there was a visible postoperative area, most likely a 
hematoma sized 24 × 12 mm. The following conditions still 
persisted: the edema of the entire lobe, a slight mass effect, 
and displacement of medial structures to the left side by 
approx. 4 mm. Also visible was the post-operative ampli-
fication of the pachymeninx in the temporal region. Apart 
from this, hemispheres of the brain and cerebellum had no 
pathological foci. The brainstem was normal. The ventricular 
system was of the correct width, not displaced, and it was 
symmetrical. The pericerebral spaces were normal. In May 
2012, the patient was admitted to the Radiotherapy Clinic, 
where he was qualified for complementary treatment of 
the site of brain tumor removal, combined with temozolo-
mide. The areas to be irradiated were determined in scans 
from the CT examination carried out in order to plan the 
treatment, as well as MRI images from before the surgery. 
The patient received a total dose of 50 Gy in 25 fractions 
of 2 Gy to the area of the contrasting tumor with edema 
(hyperintensive area in T2-weighted images in the MRI from 
before the treatment) with a two-centimeter margin PTV1 
(Planning Target Volume), using the X 6 MeV photon beam 
according to the computer plan for IMRT treatment. Next, 
due to the need to exclude critical structures from the area 
covered by the full dose, the irradiation field was reduced 
to include the tumor (T1 amplification area in the MRI) with 
a one-centimeter margin-PTV2. The total dose received by 
the patient was 60 Gy in 30 fractions of 2 Gy in six weeks 
of treatment, Monday through Friday, once a day, using 
a linear accelerator. Figure 4 and Figure 5 show paramount 
parts of treatment plan. 
During radiotherapy, the patient received 75 mg/m² of 
temozolomide for 42 days, seven days a week, starting from 
the first day of irradiation. 28 days after the end of radiother-
apy, the patient continued treatment with temozolomide at 
a dose of 150 mg/m2, i.e., for 5 days during the first treatment 
course. Next, he received five 5-day treatment courses with 
temozolomide at a dose of 200 mg/m2 with breaks of 28 days 
in-between (starting from the second course). The follow-up 
complete blood counts and biochemical blood tests during 
and after the therapy were normal. Afterward, follow-up 
brain imaging examinations were regularly performed. Fol-
low-up MRIs, during the use of temozolomide as well as after 
the treatment had finished, showed a normal image of the 
brain with demyelination changes in the region of the right 
temporal lobe (in the area operated and then irradiated). 
Follow-up imaging examinations also exclude a relapse of 
kidney cancer or dissemination of the neoplastic disease. 
The last follow-up examination of the head, performed in 
July 2018, showed a normal brain image with “a visible post-
operative fluid-filled site over an area of 37 × 23 mm, with 
Figure 4 . Treatment plan. In the top: dose-volume histogram analysis. 
Below: the table with maximum and medium doses in Planing Target 
Volume: PTV1 PTV2 and critical organs such as lens or chiasm
Figure 5 . Treatment Plan-DRR (digital reconstruction) with virtual 
simulation
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a surrounding area of gliosis, without the effect of contrast 
amplification, and without traits of local relapse”. Figure 6 
and Figure 7 show images with the last follow-up MRI study. 
The patient is still in very good general condition, WHO-0, 
in full verbal-logical contact, without any neurological 
deficits, no late manifestations related to the brain after 
the treatment. No signs of a postradiation reaction in the 
irradiated area of the scalp were detected. 
Discussion
The etiology of malignant neoplasms of the central ner-
vous system has not been fully understood yet. Hereditary 
diseases, such as type I and II neurofibromatosis, the Von 
Hippel-Lindau and the Li-Fraumeni diseases are deemed to 
be contributory to the predisposition to developing brain 
tumors [6]. Occupational exposure and environmental im-
pact are also factors increasing the risk of disease. Glioblas-
toma multiforme is a brain tumor with the worst prognosis. 
Five-year mortality is greater than 90%. The average total 
survival does not exceed 15 months [7]. It is a hypercellular 
neoplasm formed by astrocytes of poor diversification. The 
characteristic features of this neoplasm are: variable histo-
logical pattern, high proliferative activity, cellular atypy, 
proliferation of vessels creating glomerular structures, and 
presence of necrotic areas within the tumor. It is the most 
common form of gliomas, which usually develops in adults 
over 50 years of age. Typically, it is located supratentorially 
in the frontal-temporal area. It occurs particularly often in 
the white matter in the vicinity of the centrum semiovale 
and corpus callosum [6]. There are several histological sub-
types of glioblastoma multiforme (GBM): giant cell, small 
cell, pleomorphic, gemistocytic, with an oligodendroglioma 
component, gliosarcoma, and the mixed variant [2, 3]. The 
‘classical’ form of GBM and its variants are deemed to have 
the highest degree of histological malignancy (grade IV 
according to WHO). It is also one of the best known tumors 
in molecular terms. Due to the genetic mechanism, there 
is a division into the primary GBM, which can grow de novo 
and most often concerns older people, with a short history 
and usually a sudden course of the disease, and the sec-
ondary GBM, which can develop from a glioma with a low 
degree of malignancy, usually in younger people — under 
45 years of age. The first type of tumor is associated with 
excessive expression, mutations and multiplications in the 
EGFR (endothelial growth factor receptor), MDM2 genes, loss 
of heterozygosity (LOH) of 10p and 10q, as well as mutation 
of PTEN (suppressor gene) and deletion of p16. The second 
type is associated with a mutation in the p53, LOH of the 
17p, 10q and 19q genes [7]. A characteristic feature of GBM 
is the specific, infiltrating nature of growth, associated with 
the spreading of neoplastic cells in the immediate vicinity 
of the primary, solid mass of the tumor. This feature largely 
determines the poor response to both surgical and radio-
therapy treatment. Chemoradiotherapy allows to prolong 
the survival time, especially in patients with methylation 
of the gene promoter responsible for the synthesis of the 
MGMT repair enzyme (06-methylguanine-DNA-methyl-
transferase). The presence of methylation is the best known 
beneficial predictive factor [8]. Diagnostic tests performed 
on the patient: CT and MRI of the brain confirmed a single, 
small change in the brain, located outside the ventricular 
system. According to Adenberg et al., we may assume that 
Figure 6 . Last follow-up MRI — seven years after treatment. Axial T2-
weighted image. Postoperative fluid-filled site with surrounding area 
of gliosis in the right temporal lobe
Figure 7 . Last follow-up MRI — seven years after treatment. Axial T1-
weighted image. Postoperative fluid-filled site in the right temporal 
lobe
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the tumor is not in contact with the lateral ventricles if its 
shortest distance from the ventricles is greater than 10 mm 
[9]. The above imaging examinations show that GBM did 
not infiltrate the subventricular zone (SVZ), which is a very 
positive prognostic factor [9–11], because tumors which 
occupy this area grow the fastest, have a higher tendency 
to locally relapse and disseminate [11]. 
More and more studies report that the prognosis in 
some cancers is closely related to the metabolism of fats, e.g., 
in the renal cell carcinoma and the squamous cell esopha-
geal carcinoma [12]. Preoperative levels of total cholesterol 
and its individual HDL and LDL fractions in peripheral blood 
serum may be a prognostic factor also in patients suffering 
from glioblastoma multiforme [13]. In the blood tests per-
formed before the operation, the patient had a total cho-
lesterol level of 6.61 mmol/l, HDL of 1.78 mmol/l, and LDL 
of 4.65 mmol/l. According to a study by R. Liang et al. [13], 
patients with this diagnosis, who had a total cholesterol level 
of > 3.91, LDL of > 1.84 mmol/l, and HDL of > 1.32 mmol/l, 
had significantly longer total survival. This is probably due 
to the fact that cholesterol is the main component of cell 
membranes and, therefore, has a significant effect on pro-
liferation and increase in tumor mass, which results in the 
increased trapping of these substances from the blood 
and, ultimately, decreasing their level in the tested serum. 
Patients with results lower than the aforementioned values 
had significantly shorter total survivals [13]. 
Conclusion
On the basis of the presented case, we can see that it is 
possible for a patient suffering from glioblastoma multiforme 
of the brain, simultaneously combined with renal cell carci-
noma of a kidney, to survive for many years. 
We think that this was due to the occurrence of many 
positive prognostic factors in the patient. These included: 
age below 60 (at the time of diagnosis, the patient was 55 
years old), small size of the tumor, radical surgery, location of 
the lesion outside of the ventricular system of the brain, lack 
of infiltration to the subventricular zone of the brain (SVZ) as 
well as, according to recent studies, the relatively high levels 
of total cholesterol and its HDL and LDL fractions in blood 
serum from before the surgery. What is also important is that 
the patient, seven years after the treatment, is in very good 
physical and mental condition, without any neurological 
deficits, without local relapse or neoplastic dissemination 
of any of the diseases. 
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